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Varicella-zoster virus (VZV) glycoprotein gI is a type 1 transmembrane glycoprotein which is one component
of the heterodimeric gE:gI Fc receptor complex. Like VZV gE, VZV gI was phosphorylated in both VZV-infected
cells and gI-transfected cells. Preliminary studies demonstrated that a serine 343-proline 344 sequence located
within the gI cytoplasmic tail was the most likely phosphorylation site. To determine which protein kinase
catalyzed the gI phosphorylation event, we constructed a fusion protein, consisting of glutathione-S-transferase
(GST) and the gI cytoplasmic tail, called GST-gI-wt. When this fusion protein was used as a substrate for gI
phosphorylation in vitro, the results demonstrated that GST-gI-wt fusion protein was phosphorylated by a
representative cyclin-dependent kinase (CDK) called P-TEFb, a homologue of CDK1 (cdc2). When serine 343
within the serine-proline phosphorylation site was replaced with an alanine residue, the level of phosphory-
lation of the gI fusion protein was greatly reduced. Subsequent experiments with individually immunoprecipi-
tated mammalian CDKs revealed that the VZV gI fusion protein was phosphorylated best by CDK1, to a lesser
degree by CDK2, and not at all by CDK6. Transient-transfection assays carried out in the presence of the
specific CDK inhibitor roscovitine strongly supported the prior results by demonstrating a marked decrease
in gI phosphorylation while gI protein expression was unaffected. Finally, the possibility that VZV gI contained
a CDK phosphorylation site in its endodomain was of further interest because its partner, gE, contains a casein
kinase II phosphorylation site in its endodomain; prior studies have established that CDK1 can phosphorylate
casein kinase II.
Varicella-zoster virus (VZV) is a member of the alphaher-
pesvirus subfamily, which is characterized by a relatively short
replicative cycle as well as the capacity to establish latent in-
fections in neuronal cells (2, 49). McGeoch and Cook have
now divided the alphaherpesviruses into two genera: Simplex-
virus and Varicellovirus (32). VZV is the prototype of the Vari-
cellovirus genus. Two clinical syndromes have been etiologi-
cally related to human VZV infection. They include chicken
pox in children following primary viral infection and herpes
zoster in adults from reactivation of a latent viral infection in
ganglia. In cell culture, VZV is notoriously cell associated;
although titers of infectious virus are invariably low, VZV
replicates best in cells which are themselves continuing to
divide (16). To date, six VZV glycoproteins have been char-
acterized (11, 15). They are gE, gB, gH, gI, gC, and gL, which
are named after their herpes simplex virus (HSV) counterparts
(7, 49). However, only five of them are membrane associated;
VZV gL is a cytoplasmic glycoprotein (11).
VZV gE and gI were formerly called gpI and gpIV, respec-
tively. Both of them are type 1 transmembrane glycoproteins.
In virus-infected cells as well as in transiently transfected cells,
gE and gI have been shown to associate with each other to
form a heterodimer, and this complex behaves as an Fc recep-
tor when it appears on the cell surface (28, 57). A recent study
indicates that the amino-terminal end of the extracellular do-
main of gI is important for association with VZV gE (21). Like
many other cell surface receptors, both gE and gI undergo
endocytosis in a pattern mimicking the human transferrin re-
ceptor; in the presence of gI, the amount of internalized gE is
greatly increased (1, 42, 43). Studies with mutant viruses indi-
cate that VZV gE is essential for viral assembly in tissue
culture while gI is dispensable. However, both gE and gI are
required for the virus to spread cell to cell, and gI is important
for the proper cytoplasmic distribution of gE (6, 29).
In addition, VZV gE and gI share another interesting fea-
ture of nonviral cell surface receptors: both are phosphorylated
(15, 57). Monomeric high-mannose and mature forms of gE
are phosphorylated on the endodomain by a serine protein
kinase, while an underglycosylated dimeric gE complex is mod-
ified by a tyrosine protein kinase (15, 42, 58). A computer-
assisted homology search followed by site-directed mutagene-
sis of the gE cytoplasmic tail defined a prototypic serine-
threonine consensus sequence for casein kinase II (CKII)
phosphorylation; the authenticity of this site was verified by
blotting the attached kinase with CKII-specific antibody (41).
In contrast to that of gE, phosphorylation of VZV gI is less
well understood. Previous work carried out in our laboratory
indicated that a tailless gI mutant was not phosphorylated;
although the endodomain does not contain a CKII phosphor-
ylation motif, a serine-proline sequence within the cytoplasmic
tail was a potential phosphorylation site (56). Although the
protein kinase phosphorylating gI remains to be determined,
the fact that a serine-proline sequence is a cyclin-dependent
kinase (CDK) consensus phosphorylation site is particularly
interesting in light of the highly cell-associated nature of this
reclusive herpesvirus.
MATERIALS AND METHODS
Viruses, cells, and antibodies. The MeWo strain of human melanoma cells is
a preferred cell substrate for propagation of VZV (16). HeLa cells were obtained
from the American Type Culture Collection and grown in Eagle’s minimum
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essential medium; human embryonic kidney 293T cells were maintained in Dul-
becco modified minimum essential medium (44). Human CEM and Jurkat lym-
phocyte cells were maintained as described previously (18, 37). The VZV-32
strain was isolated from a child with chicken pox (16). Characterization of the
anti-gI monoclonal antibody (MAb) 6B5 has been described previously (28).
Rabbit antiserum against VZV gI was prepared in our laboratory by immunizing
a rabbit with gI expressed by recombinant vaccinia virus. Antibodies to CDK1,
CDK2, and CDK6 were produced as described previously (18).
Labeling of VZV gI with [32P]orthophosphate. MeWo cells were seeded into
a 25-cm2 monolayer and grown to 75% confluence. The cells were inoculated
with VZV-32 strain-infected cells at a ratio of 1 infected cell to 10 uninfected
cells. When 50% of the cells displayed cytopathic effect, the medium was re-
placed with fresh medium containing 500 mCi of [32P]orthophosphate/ml (10
mCi/ml; Amersham Life Science). The radiolabeling was continued for an ad-
ditional 2 days, after which the cells were harvested for preparation of cell lysates
in radioimmunoprecipitation assay (RIPA) buffer. Immunoprecipitation and so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) were car-
ried out as described previously (56, 57).
Transfection of HeLa cells with vaccinia-pTM1 plasmids. The pTM1 plasmid
was received from B. Moss, National Institutes of Health, Bethesda, Md. (12, 36).
We previously described plasmids pTM1-gI, pTM1-gI-S343A, pTM1-gI-P344A,
and pTM1-gI-P345A, as well as the methodology for Lipofectin-mediated trans-
fection of HeLa cells (56). Plasmids pTM1-gI-T322A and pTM1-gI-T322A/
S343A were constructed by a recombination PCR method for site-directed mu-
tagenesis as described previously (59). Plasmids pTM1-gI and pTM1-gI-S343A
were the templates for PCR mutagenesis. The mutation primer for the sense
strand was 59-CAAAATGCTGCACCAGAATCCGATG-39, and the mutation
primer for the antisense strand was 59-GATTCTGGTGCAGCATTTTGTATG
CC-39. The nonmutation primer for the sense strand of the beta-lactamase gene
was 59-GGGTGCACGAGTGGGTTACATC-39, and the nonmutation primer
for the antisense strand of the beta-lactamase gene was 59-GATGTAACCCAC
TCGTGCACCCAACTGAT-39. After mutagenesis, the resulting plasmids,
pTM1-gI-T322A and pTM1-gI-T322A/S343A, were subjected to DNA sequenc-
ing through the mutation; both exhibited a single-amino-acid change from thre-
onine to alanine at position 322.
To transfect HeLa cells with pTM1-based recombinant plasmids, 6.2 3 105
HeLa cells were seeded into each well of a six-well tissue culture plate 16 h
before transfection. The cells were then washed twice with 5% fetal bovine serum
containing Eagle’s essential medium. The washed cells were subsequently in-
fected with 2.5 3 107 PFU of recombinant vaccinia virus encoding bacterial
phage T7 RNA polymerase (12, 36). After a 30-min incubation at 37°C, the virus
was removed and the cells were washed once. After the addition of 1 ml of
medium into each well, 30 ml of DNA-Lipofectin (Life Technologies) mixture
was added to each monolayer. The DNA-Lipofectin mixture was prepared by
mixing 4 mg of DNA in 15 ml of water with 15 ml of 30% Lipofectin. The cultures
were incubated at 37°C for 6 h, after which the cells were labeled for 16 h with
35S-Promix ([35S]methionine and [35S]cysteine; .1,000 Ci/mmol) (Amersham)
or [32P]orthophosphate.
Construction of plasmids pCDNA-gI and pCDNA-gI-S343A. Recombinant
plasmid pCDNA-gI was constructed by inserting the VZV gI gene from plasmid
pTM1-gI into a eukaryotic expression vector, pCDNA3 (Invitrogen). Briefly, two
primers were synthesized. The primer sequence corresponding to the 59 end of
the gI coding region was 59-GCCGGATCCACGATGGTTTTAATCCAATGT
TTG-39. A restriction site, BamHI (underlined), was added to the 59 end of the
primer. A minor change was also made in the coding region by replacing nucle-
otide T with G at the plus-4 position of the open reading frame as well as
substituting A for G at position minus 3 of the 59 noncoding region so that the
translation signal was the same as the consensus sequence defined by Kozak (22).
The primer sequence corresponding to the 39 end of the coding region was:
59-GCGCGCTCGAGCTATTTAACAAACGGGTTTACAAC-39. A restriction
site, XhoI (underlined in the primer sequence), was added to the 59 end of the
primer. The gene coding for VZV gI was amplified from pTM1-gI with the
above-mentioned two primers. After the amplified gI gene was inserted into
vector pCDNA3 at restriction sites BamHI and XhoI, the resulting recombinant
plasmid was designated pCDNA-gI. Recombinant plasmid pCDNA-gI-S343A
was similarly constructed, except that the pTM1-gI-S343A plasmid was used as a
template from which to amplify the mutant gene gI-S343A.
Transfection of a human embryonic kidney cell line. 293T cells were trans-
fected with pCDNA-gI or pCDNA-gI-S343A DNA by either a CaCl2-HBS or a
Lipofectin transfection method (50, 56). Briefly, 293T cells were subcultured the
day before transfection into 60-mm-diameter culture dishes. At the time of
transfection, the 293T cell monolayers were 30 to 40% confluent. About 30 min
before transfection, the DNA-CaCl solution was prepared by first mixing 10 mg
of plasmid DNA in 25 ml of water; the 25-ml volume was added to 500 ml of 23
HBS (25 mM Hepes, 140 mM NaCl, 5 mM KCl, 0.75 mM Na2HPO4 [pH 7.05],
6 mM dextrose). Thereafter, 475 ml of 250 mM CaCl2 was added to the 525-ml
volume. The 1-ml DNA suspension was added to the monolayer in a dropwise
fashion, and the transfected cells were incubated at 37°C. Alternatively, 293T
cells were transfected by a Lipofectin-mediated method as suggested by the
manufacturer for the study of phosphorylation. At 6 h posttransfection, the cells
can be labeled with [32P]orthophosphate or 35S-Promix. At 48 h posttransfection,
the transfected cells were examined by confocal microscopy or harvested for
preparation of cell lysates for an immunoprecipitation assay.
Construction of recombinant plasmid GST-gI fusion protein. A recombinant
plasmid expressing the glutathione-S-transferase (GST)-gI fusion protein was
constructed by amplifying the cytoplasmic tail of the gI gene in pTM1-gI and
inserting the DNA fragment into vector pGEX-4T-1 (Pharmacia) at BamHI and
XhoI sites (see Fig. 6). Briefly, two primers were synthesized to amplify the
desired portion of the gI gene. The primer sequence corresponding to the amino
end of the cytoplasmic tail of gI protein is 59-GGCCGGGATCCATAAGCGT
TAAGCGACGTAGA-39. A restriction site, BamHI (underlined in the se-
quence), was introduced at the 59 end of the primer. The primer corresponding
to the carboxy-terminal end of the gI protein is 59-GCGCGCTCGAGCTATTT
AACAAACGGGTTTACAAC-39. A restriction site, XhoI (underlined in the
sequence), was inserted in the primer. With the above-mentioned two primers,
the DNA fragment corresponding to the cytoplasmic tail of the VZV gI gene was
amplified and inserted into expression vector pGEX-4T-1 at restriction sites
BamHI and XhoI; the recombinant plasmid was designated pGST-gI-wt. Plasmid
pGST-gI-S343A was similarly constructed, except that pTM1-gI-S343A was used
as a template to amplify the DNA fragment coding for the cytoplasmic tail of the
gI protein.
After recombinant plasmids pGST-gI-wt and pGST-gI-S343A were con-
structed, they were subsequently transformed into Escherichia coli BL21/DE3.
Positive clones were verified by a PCR method. To induce the fusion protein, one
colony was picked and inoculated into 5 ml of Circlegrow medium (Bio101). The
cells were incubated at 30°C overnight. The next day, 2 ml of the liquid culture
was transferred to a 100-ml container of Circlegrow medium and incubated for
an additional 4 h at 30°C. When the optical density at 600 nm reached 1.0, 0.1
mM IPTG (isopropyl-b-D-thiogalactopyranoside) was added to the cells. The
cells were pelleted after 3 h of induction and were subsequently lysed by a
sonication method. The fusion protein in the lysate was purified by a glutathione-
Sepharose 4B affinity column (Pharmacia) under conditions suggested by the
manufacturer. Verification of the authenticity of the gI fusion protein was per-
formed by immunoblotting procedures described in this laboratory (28).
Kinase assay with P-TEFb. The kinase P-TEFb was purified as described by
Marshall et al. (30, 31). To perform the kinase assay, 100 ml of bacterial cell
lysate containing GST-gI fusion protein was incubated with 20 ml of 50% gluta-
thione-Sepharose 4B beads at 4°C for 30 min. The beads were washed three
times with 300 ml of STE buffer (100 mM NaCl, 10 mM Tris-HCl [pH 8.0], 1 mM
EDTA) and once with kinase buffer (100 mM Tris-acetate [pH 7.5], 10 mM
magnesium acetate). The kinase assay was continued by adding 78 ml of kinase
buffer, 1 ml of 28 mM P-TEFb, and 10 mCi of [g-32P]ATP. After the reaction had
proceeded at 30°C for 30 min, the beads were washed four times with 500 ml of
STE buffer. Then, 100 ml of loading buffer (0.125 M Tris [pH 6.8], 6% SDS, 20%
glycerol, 0.5% bromophenol blue) was added to the beads, and the beads were
boiled in a water bath for 5 min. The protein was resolved by 12 to 18% gradient
SDS-PAGE.
Immunoprecipitation kinase assay with CDKs. The coupled immunoprecipi-
tation kinase assays were performed similarly to those previously described (20,
46). Briefly, CEM or Jurkat cell lysates containing 300 mg of total protein were
immunoprecipitated for 16 h with rabbit serum against CDK1, CDK2, or CDK6
and incubated for 3 h with protein A-Sepharose beads (Sigma) (20). Peptide
competition was performed by preincubating the rabbit antiserum for 10 min
with the peptide against which it was raised (46). Subsequently, the kinase assays
were performed with histone H1 (Boehringer Mannheim) or GST fusion pro-
teins employed as the substrate (46). The phosphorylated substrates were re-
solved by SDS-PAGE and analyzed with a phosphorimager; subsequently, the
gels were exposed to film.
Roscovitine treatment of transfected cells. HeLa cell monolayers in six-well
plates were transfected with 4 mg of pTM1 or pTM1-gI DNA as described above.
After transfection had proceeded for 6 h, the cells were either left untreated or
treated with 15 or 30 mM roscovitine (Calbiochem) in medium containing
[32P]orthophosphate or 35S-Promix. The monolayers were lysed 16 h later with
RIPA buffer containing 50 mM NaF. Immunoprecipitation of gI and autoradiog-
raphy were carried out as previously described.
Confocal microscopy. Laser scanning confocal microscopy of transfected cells
was carried out by methods described in an earlier publication by Duus and
Grose (11). The Bio-Rad 1024 confocal microscope is located in the Central
Microscopy Research Facility of the University of Iowa.
RESULTS
Phosphorylation of VZV gI in infected and transfected cells.
To demonstrate the fact that VZV gI was phosphorylated,
MeWo cells were infected with strain VZV-32 and then la-
beled metabolically with [32P]orthophosphate. After lysis of
the infected cells with RIPA buffer, aliquots of the cell lysate
were incubated with MAb 6B5 to immunoprecipitate VZV gI.
When immunoprecipitated gI was subjected to SDS-PAGE
and autoradiography, a radioactive protein corresponding to
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VZV gI was detected (Fig. 1A, lanes 1 and 2). As has been
reported, VZV gE, which migrates as two broad bands be-
tween 83 and 98 kDa, coprecipitated with gI (57). Because the
VZV genome encodes putative protein kinases, we wished to
determine whether gI was phosphorylated in the absence of
other VZV proteins. For this experiment, we investigated the
extent of VZV gI phosphorylation after subcloning the VZV gI
gene into a eukaryotic expression vector, pTM1, resulting in a
recombinant plasmid, pTM1-gI (56). Thereafter, the pTM1-gI
plasmid was transfected into HeLa cells which were prein-
fected with a recombinant vaccinia virus expressing bacterio-
phage T7 RNA polymerase. The transfected cells were labeled
with [32P]orthophosphate, and VZV gI was immunoprecipi-
tated with MAb 6B5. As in VZV-infected cells, VZV gI was
phosphorylated (Fig. 1B, lane 4). When HeLa cells were co-
transfected with pTM1-gI and pTM1-gE, both gI and gE were
phosphorylated (Fig. 1B, lane 3). In addition, as in infected
cells, gE was coprecipitated with VZV gI, a result which con-
firmed that VZV gI associated with gE in transfected cells.
Phosphorylation of VZV gI by a cellular kinase. Since the
phosphorylation studies of VZV gI shown in Fig. 1 were con-
ducted in either VZV-infected cells or vaccinia virus-infected
and transfected cells, it remained to be determined whether gI
was phosphorylated by a cellular kinase or possibly by a kinase
originating from vaccinia virus (3, 24, 39, 53). To circumvent
the obstacles concerning the origin of the kinase, we subcloned
the gI gene from the pTM1-gI recombinant plasmid into an-
other eukaryotic expression vector, pCDNA3; the resultant
plasmid was called pCDNA-gI. To assure a high expression of
gI protein in transfected cells, we made minor modifications in
the nucleotide sequence around the initiation methionine
codon ATG (underlined). The modification resulted in a
change in nucleotide sequence from GCGATGT to ACGAT
GG, the latter being a consensus sequence required for trans-
lation signaling as defined by Kozak (22). This modification led
to a change of a phenylalanine at the second position, the
amino acid immediately after the first methionine, into a va-
line. Since this amino acid is located within the deduced signal
sequence which will be cleaved in the endoplasmic reticulum,
the mature VZV gI protein encoded by the modified gene
should not differ in sequence from the product of the wild-type
gene (7, 21). We transfected the plasmid pCDNA-gI into hu-
man 293T cells and examined gI protein expression by laser
scanning confocal microscopy. As shown in Fig. 2, at least 70%
FIG. 1. Phosphorylation of gI in VZV-infected cells and in transfected cells.
(A) MeWo cells were infected with VZV and labeled with [32P]orthophosphate.
After lysis of the cells with RIPA buffer, the indicated amounts of cell lysate were
incubated with MAb 6B5 and subsequently with protein A-Sepharose CL-4B
beads. The precipitates were resolved by SDS-PAGE (12% acrylamide) and
subjected to autoradiography. (B) HeLa cells were transfected with pTM1 vector
alone (lane 5) or pTM1-gI alone (lane 4) or cotransfected with pTM1-gI and
pTM1-gE (lane 3) and labeled with [32P]orthophosphate. Immunoprecipitation
of gI was performed as described for panel A. Proteins corresponding to VZV gE
and gI are indicated with arrows; molecular mass markers are indicated by solid
circles.
FIG. 2. Expression of VZV gI in 293T cells. Human 293T cells were trans-
fected with pCDNA3 (A), pCDNA-gI (B), or pCDNA-gI-S343A (C). Immuno-
labeling was carried out with MAb 6B5 against VZV gI; the secondary antibody
was an Oregon green-conjugated sheep anti-mouse reagent. Subsequently the
cells were examined with a laser scanning confocal microscope at 320 magnifi-
cation. Green represents expressed gI, and red designates nuclei stained with
ethidium bromide.
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of the cells expressed wild-type gI (compare Fig. 2A and B).
The majority of the gI-transfected cells had high levels of
fluorescence staining, demonstrating that the gI protein was
expressed abundantly in 293T cells. At the same time, we
compared the expression of wild-type VZV gI in 293T cells
with that in HeLa cells, the substrate in which many previous
experiments had been carried out (Fig. 3A). The degrees of
wild-type gI expression in both transfection systems were sim-
ilar. This comparison was performed, in part, in order to allay
concerns that the pTM1 expression system may not be an
accurate indicator of the usual gI trafficking patterns.
With the success of this alternative transfection system, we
then investigated whether gI was phosphorylated in 293T cells.
After 293T cells were transfected with pCDNA-gI, they were
FIG. 3. Cytoplasmic expression of wild-type and mutant VZV gI proteins. HeLa cells were transfected with plasmids pTM1-gI (A), pTM1-gI-S343A (B),
pTM1-gI-P344A (C), and pTM1-gI-P345A (D). Immunolabeling was performed with MAb 6B5 and Oregon green-tagged sheep anti-mouse antibody. The cells were
examined by a confocal microscope at 360 magnification. Green indicates gI, while the nuclei are stained red with ethidium bromide. Cells transfected with vector alone
had no green staining (data not shown; see Fig. 2A).
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labeled with [32P]orthophosphate. At 48 h posttransfection, the
cultures were harvested and analyzed by an immunoprecipita-
tion assay followed by autoradiography. As shown in Fig. 4, a
phosphoprotein band corresponding to VZV gI was detected
(lane 2), a result which indicated that VZV gI was phosphor-
ylated in 293T cells. There was no phosphorylation of the
vector alone (lane 1). Since VZV gI was phosphorylated in the
absence of VZV or vaccinia virus infection, the viral protein
was obviously phosphorylated by a cellular kinase in 293T cells.
Serine-proline consensus phosphorylation sequence. Previ-
ously, some mutations were made within the gI gene in the
pTM1-gI recombinant plasmid (56). These mutations had
never been examined under the sensitive laser scanning con-
focal microscope to compare expression. Therefore, three mu-
tant gI recombinant plasmids, pTM1-gI-S343A, pTM1-gI-
P344A, and pTM1-gI-P345A, were transfected into HeLa cells
and observed by confocal microscopy after permeabilization
(Fig. 3). Levels of expression appeared comparable for the
wild-type gI (Fig. 3A) and all three mutant proteins (gI-S343A
[Fig. 3B], gI-P344A [Fig. 3C], and gI-P345A [Fig. 3D]). When
examined by optical tomography, all of them were similarly
distributed in the cytoplasm and all exhibited similar fluores-
cence labeling on the membrane. Next, the same transfection
experiment was repeated, but the cultures were labeled meta-
bolically with [32P]orthophosphate. After immunoprecipitation
and autoradiography, the phosphorylation status of each mu-
tant gI protein was compared with that of wild-type gI. As
shown in Fig. 5, the phosphorylation signals of all mutant gI
proteins (lanes 3, 4, and 5) were much lower than that of the
wild-type (lane 2); there was no phosphorylation of vector
alone (lane 1). Furthermore, a difference in signal reduction
was calculated based on phosphorimaging analysis; i.e., phos-
phorylation signals of gI-S343A and gI-P344A were about 10%
of that seen with wild-type gI, while that of gI-P345A was about
30% of that of the wild type. These results indicated that both
serine residue 343 and proline residue 344 were essential for
the phosphorylation of gI. In contrast, proline 345 modulated,
but did not abrogate, the phosphorylation of VZV gI. In other
words, the phosphorylation site within gI consisted primarily of
the serine 343-proline 344 sequence.
Even though VZV gI was phosphorylated both in vaccinia
virus-infected HeLa cells and in transfected 293T cells, there
was a possibility that gI was phosphorylated at one site in HeLa
cells and at a second site in non-vaccinia virus-infected 293T
cells. To exclude this possibility, we subcloned the gI-S343A
mutant gene into the pCDNA3 vector; the new construct was
called pCDNA-gI-S343A. As with each new construct de-
scribed previously, expression of the mutant gI protein was
analyzed first by confocal microscopy (Fig. 2C). We next trans-
fected both wild-type pCDNA-gI and mutant pCDNA-gI-
S343A into 293T cells and metabolically labeled the cultures
with either [32P]orthophosphate or 35S-Promix. When serine
343 was replaced with an alanine, the phosphorylation signal
was greatly reduced compared with that of wild-type gI. This
reduction of phosphorylation was not the result of decreased
protein production, because the expression levels in wild-type
gI and mutant gI-S343A were similar, as shown by optical
tomography (Fig. 2B and C) and in 35S-Promix-labeled protein
gels (data not shown). These results were most consistent with
the interpretation that the serine 343-proline 344 sequence was
essential for the phosphorylation of VZV gI.
Phosphorylation of VZV gI-GST fusion proteins. After the
phosphorylation site was localized and the cellular origin of the
kinase was determined, our next aim was to identify the nature
of the cellular kinase phosphorylating VZV gI protein at serine
343-proline 344. An in vitro kinase assay was required for this
purpose. To obtain the large amount of substrate required for
individual protein kinase assays, we constructed GST-gI fusion
proteins. Since the phosphorylation site within gI is located at
the cytoplasmic tail, we amplified the DNA fragment coding
for the cytoplasmic tail of gI. The resulting DNA fragment was
inserted into an expression vector, pGEX-4T-1, at compatible
sites (Fig. 6). Two fusion proteins were constructed, GST-gI-wt
and GST-gI-S343A. GST-gI-wt is a fusion protein of GST and
the cytoplasmic tail of wild-type gI, and GST-gI-S343A is a
fusion protein of GST and the cytoplasmic tail of mutant gI-
S343A.
Coomassie brilliant blue staining of an acrylamide gel dem-
FIG. 4. Phosphorylation of VZV gI by a cellular kinase. Human 293T cells
were transfected with plasmids pCDNA3 (lane 1), pCDNA-gI (lane 2), or
pCDNA-gI-S343A (lane 3). The cells were labeled with [32P]orthophosphate and
harvested with RIPA buffer. VZV gI was immunoprecipitated with MAb 6B5
and analyzed by SDS-PAGE (12 to 18% gradient acrylamide) followed by au-
toradiography. The migration of gI is indicated with an arrow. Molecular mass
markers are on the right.
FIG. 5. Effect of mutagenesis of serine 343 and proline 344 on the phosphor-
ylation of VZV gI. HeLa cells were transfected with plasmids pTM1 (lane 1),
pTM1-gI (lane 2), pTM1-gI-S343A (lane 3), pTM1-gI-P344A (lane 4), and
pTM1-gI-P345A (lane 5). The transfected cells were labeled with [32P]ortho-
phosphate. VZV gI was immunoprecipitated with MAb 6B5 and analyzed by
SDS-PAGE (12% acrylamide) followed by autoradiography. VZV gI is desig-
nated with an arrow. Molecular mass markers are on the right.
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onstrated that the purified proteins were the correct size: both
GST-gI and GST-gI-S343A migrated at a molecular mass of 33
kDa (Fig. 7A, lanes 2 and 3). To verify that GST and the
cytoplasmic tail of gI were fused in frame, we performed West-
ern blot analysis with rabbit antiserum against gI. Protein
bands corresponding to GST-gI-wt in a Coomassie blue-
stained gel reacted with the anti-gI antibody (Fig. 7B, lane 5).
In a separate experiment, immunoblotting was also performed
with GST-gI-S343A and the result was similarly positive (Fig.
7B, lane 6). These findings indicated that both the wild-type
fusion protein GST-gI-wt and the mutant fusion protein GST-
gI-S343A were correctly constructed.
Phosphorylation of VZV gI by a Drosophila kinase homolo-
gous to CDK1. After fusion proteins containing GST and the
cytoplasmic tail of gI were successfully expressed, we deter-
mined whether they were phosphorylated by a cellular kinase.
Since the putative phosphorylation site within VZV gI is iden-
tical to a consensus sequence phosphorylated by CDKs, we
examined the ability of a CDK to phosphorylate the target site
within gI when it is provided in the form of GST-gI-wt fusion
protein. Recently, genetically similar Drosophila and human
kinases homologous to CDK1 (cdc2) were identified and par-
tially characterized (30, 31, 45, 60). They were initially named
positive transcription elongation factor b (P-TEFb) but are
now called CDK9 and cyclin T complex. Since this kinase is
highly homologous to other CDKs (see Discussion), it was a
potentially valuable reagent to examine phosphorylation of the
target site in the GST-gI-wt fusion protein. When a kinase
assay was performed with purified P-TEFb, the results dem-
onstrated that GST-gI-wt was phosphorylated (Fig. 8, lane 2)
while the vector alone was not phosphorylated (Fig. 8, lane 1).
When the mutant fusion protein GST-gI-S343A was similarly
tested, the phosphorylation signal was 30% that of wild-type
GST-gI-wt fusion protein (Fig. 8, compare lane 2 with lane 3).
These results indicated that the serine 343 residue within GST-
gI-wt strongly influenced phosphorylation by the P-TEFb ki-
nase.
Phosphorylation of fusion protein GST-gI-wt by CDK1 and
CDK2. Since the catalytic domain of Drosophila P-TEFb has
the highest sequence homology with CDK1 and CDK2, we
next investigated whether GST-gI-wt was phosphorylated by
these two human CDKs. To perform this experiment, CDK1
and CDK2 were individually precipitated from a lysed leuke-
mia cell line, CEM, with rabbit serum directed against an
epitope of CDK1 or CDK2. These kinase preparations were
then added to in vitro kinase assays. Figure 9 illustrates the
results of the kinase assays for both CDK2 (lanes 1 to 4) and
CDK1 (lanes 5 to 8). As shown in lanes 2 and 6, respectively,
the GST-gI-wt protein was phosphorylated by both CDK2 and
CDK1. In the negative controls lacking kinases in the reaction
FIG. 6. Construction of a recombinant plasmid expressing GST-gI fusion
protein. The DNA sequence encoding the cytoplasmic tail of VZV gI was
amplified by PCR technology with primers P1 and P2. A BamHI site was inserted
into the 59 end of primer P1, and a XhoI site was inserted into the 59 end of
primer P2. The amplified DNA fragment was inserted into vector pGEX-4T-1 at
compatible sites: BamHI and XhoI sites (underlined). The resulting recombinant
plasmid, pGST-gI, encodes a fusion protein consisting of GST with the gI cyto-
plasmic tail.
FIG. 7. Analysis of the fusion proteins GST-gI-wt and GST-gI-S343A. Puri-
fied GST (lanes 1 and 4), GST-gI-wt (lanes 2 and 5), and pGST-gI-S343A (lanes
3 and 6) were stained with Coomassie brilliant blue (A) or analyzed by immu-
noblotting with a rabbit serum against gI (B). The arrowheads designate the
GST-gI fusion proteins. Molecular mass markers are on the right and left.
FIG. 8. Phosphorylation of GST-gI-wt by a Drosophila CDK homologue.
Drosophila P-TEFb is a homologue of the mammalian CDK which has been
recently designated CDK9. GST (lane 1), GST-gI-wt (lane 2), and GST-gI-
S343A (lane 3) were purified with glutathione-Sepharose 4B beads. The kinase
assay was performed as described in Materials and Methods, and the phosphor-
ylated proteins were identified by autoradiography. The positions of GST and
GST-gI fusion proteins are indicated with arrows. The biological substrate of
CDK9 is the carboxy-terminal domain of the largest subunit of RNA polymerase
II; its phosphorylation is shown in reference 45. Molecular mass markers are on
the right.
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mixtures, no phosphorylation signals were detected (lanes 1
and 5). In the positive controls in lanes 4 and 8, respectively,
histone H1 was strongly phosphorylated by both CDK2 and
CDK1.
There was a possibility that a kinase other than a CDK was
present in the immunoprecipitate and phosphorylated GST-
gI-wt. To exclude this possibility, a competition assay was per-
formed, in which the anti-CDK2 or anti-CDK1 antibody was
incubated with CDK2 or CDK1 epitope peptides for 10 min.
These antigen-antibody mixtures were subsequently incubated
with CEM cell lysate as before. Each resulting immunoprecipi-
tate was tested for its ability to phosphorylate GST-gI-wt. As
shown in Fig. 9, lane 3, preincubation of the anti-CDK2 anti-
body with the epitope peptide used to generate the antibody
led to suppression in the competition assay and eliminated the
phosphorylation of GST-gI-wt. Similarly, as shown in Fig. 9,
lane 7, preincubation of the anti-CDK1 antibody with the
epitope peptide used to generate the antibody led to suppres-
sion in the competition assay and abrogated the phosphoryla-
tion of GST-gI-wt. Thus, the competition assays reinforced the
specificity of the CDK in vitro phosphorylation assays.
Preferential phosphorylation of the serine 343-proline 344 se-
quence. In vitro kinase assays demonstrated that the serine 343
residue strongly influenced phosphorylation by the P-TEFb
kinase. To investigate whether the same serine residue affected
phosphorylation by CDK1, kinase assays with CDK1 were per-
formed with substrates GST, GST-gI-wt, and GST-gI-S343A.
Similarly to transfected cells, GST-gI-wt was phosphorylated
by CDK1, while GST itself was not phosphorylated (Fig. 10A,
lanes 2 and 3). Although GST-gI-S343A was also phosphory-
lated, the phosphorylation signal of GST-gI-wt was fivefold
higher than that of GST-gI-S343A when the radioactivities of
the two proteins were measured quantitatively (Fig. 10A, lanes
3 and 4). Again, this result suggested that GST-gI-wt was
phosphorylated by CDK1 mainly at the serine 343-proline 344
sequence. To determine whether wild-type gI was also phos-
phorylated by CDK2, we performed a similar kinase assay with
GST, GST-gI-wt, and GST-gI-S343A (Fig. 10A, lanes 6 to 8).
As can be seen, the phosphorylation signal of GST-gI-wt was
about twofold higher than that of GST-gI-S343A (Fig. 10A,
lanes 7 and 8).
When the phosphorylation signals of GST-gI-wt by CDK1
and CDK2 were compared, a large difference was apparent
(Fig. 9 and 10A). A fourfold-higher phosphorylation signal
accompanied CDK1 in the protein kinase assay. Two factors
could account for the observed differences. The first is that
GST-gI-wt is the preferred substrate for CDK1 rather than
CDK2. The second is that more CDK1 activity than CDK2
activity was present during the immunoprecipitation kinase
assay. To rule out the second possibility, we examined the
relative phosphorylation of histone H1 by CDK1 and CDK2
isolated by the above-described immunoprecipitation meth-
od. After CDK1 and CDK2 kinases were prepared, various
amounts of substrate histone H1 were tested, as shown in Fig.
10B. If there is a difference in activity between CDK1 and
CDK2, there will be a constant difference in the phosphoryla-
tion signals at each concentration of histone H1. The result of
the kinase assay indicated that even 1 mg of histone H1 pro-
vided sufficient substrate for CDK1 and CDK2 under the con-
ditions of the kinase assay (Fig. 10B, lanes 5 and 6). An in-
crease in the amount of substrate histone H1 did not increase
the phosphorylation signals generated by CDK1 and CDK2.
With all three concentrations of substrate, both CDKs gener-
FIG. 9. Phosphorylation of the fusion protein GST-gI by CDK1 and CDK2.
The coupled immunoprecipitation kinase assay was performed as described in
Materials and Methods. The constituents in each assay are listed in tabular
format above each lane at the top of the figure (1, present; 2, absent). CDK2
was present in lanes 2 to 4; CDK1 was present in lanes 6 to 8. Histone H1 was
the artificial substrate for the positive-control assays in lanes 4 and 8. The nega-
tive-control lanes 1 and 5 contain only GST-gI protein. For the competition
assay, antibodies against CDK2 or CDK1 were preincubated for 10 min with an
epitope peptide of CDK2 (lane 3) or CDK1 (lane 7). The locations of GST-gI and
histone are indicated in the right margin. Molecular mass markers are on the left.
FIG. 10. Phosphorylation of GST-gI-wt and mutant proteins. (A) Kinase
assays were performed as described for Fig. 9. CDK1 is the kinase in lanes 2 to
4, and CDK2 is the kinase in lanes 6 to 8; the substrates include GST in lanes 2
and 6, GST-gI-wt in lanes 3 and 7, and GST-gI-S343A in lanes 4 and 8. Histone
H1 was incubated with a mock kinase preparation lacking both CDK1 and CDK2
in lane 5. Lane 1 includes markers. (B) CDK phosphorylation of histone H1
substrate. Decreasing amounts of substrate were added to the kinase assays illu-
strated in lanes 1 to 6. The arrows in the right margin are labeled as follows: I,
VZV gI; G, GST; and H, histone substrate. Molecular mass markers are on the left.
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ated similar phosphorylation signals. Therefore, we concluded
that the CDK1 and CDK2 preparations contained similar hi-
stone H1 kinase activity, and consequently the different phos-
phorylation signals detected with the GST-gI-wt substrate were
most likely the result of phosphorylation site preferences.
To further investigate CDK substrate specificity, we tested
whether gI was phosphorylated by another CDK less homolo-
gous to CDK1 or CDK2. In the same manner as described for
CDK1 and CDK2, CDK6 was isolated by immunoprecipitation
from either Jurkat cells or CEM cells and placed in an in vitro
protein kinase assay. The results of this kinase assay are shown
in Fig. 11: there was no phosphorylation of GST-gI-wt by
Jurkat-derived CDK6 (lane 2), while CEM-derived CDK6
showed a similar negative result (lane 4). There was also no
GST phosphorylation by CDK6 (lane 3). Therefore, CDK spe-
cificity was further documented when GST-gI-wt was a sub-
strate in the coupled immunoprecipitation protein kinase as-
say.
Investigation of a threonine-proline sequence within VZV
gI. In the kinase assays shown in the preceding figures, a weak
phosphorylation signal was occasionally present when GST-gI-
S343A was tested as a substrate. To investigate whether an
alternative CDK phosphorylation site was present in gI, we
reexamined the amino acid sequence of the cytoplasmic tail. A
threonine-proline sequence at positions 322 and 323 was iden-
tified (Fig. 12A). To determine whether the threonine-proline
sequence was a utilized phosphorylation site, we performed
site-directed mutagenesis in genes coding for both wild-type gI
and mutant gI-S343A. The resulting mutants were named
VZV gI-T322A and gI-T322A/S343A, where threonine-322
was replaced by an alanine in both wild-type gI and mutant
gI-S343A. When the wild-type and mutant genes were subse-
quently transfected into HeLa cells and labeled with [32P]
orthophosphate, the phosphorylation signals of wild-type gI
and the gI-T322A mutant were equally strong (Fig. 12B, lanes
2 and 4); in other words, deletion of the threonine-proline
sequence exerted no effect on in vivo phosphorylation. As
previously shown (Fig. 5), mutation of serine 343 within the
gI-S343A construct resulted in abrogation of phosphorylation
(Fig. 12B, lane 3). Similarly, no phosphorylation occurred in
the double mutant gI-T322A/S343A (Fig. 12, lane 5).
In addition, previously published data have described two
independent single mutations which involved the replacement
of either serine 296 or threonine 338 with an alanine residue
within the gI tail; neither substitution affected the in vivo phos-
phorylation of gI (56). In further experiments, serine 347 was
replaced with an alanine; again, no decrease of the in vivo
phosphorylation signal in this mutant gI was observed com-
pared with that of wild-type gI (data not shown). Therefore,
the in vivo phosphorylation experiments failed to detect addi-
tional potential phosphorylation sites in the cytoplasmic tail of
VZV gI. The same in vivo phosphorylation data suggested that
the minimal phosphorylation of the mutant gI construct seen in
the in vitro kinase assays was not related to an authentic phos-
phorylation site.
Inhibition of gI phosphorylation by roscovitine. In order to
confirm the above results, which suggested that VZV gI was a
physiological substrate of a CDK, experiments with a specific
CDK inhibitor were next performed. Roscovitine, a purine
analog, has been identified as a potent selective inhibitor of the
kinase activities of CDK1, CDK2, and CDK5 but much less so
for those of CDK4 or CDK6 (9, 33). Treatment of cells with
roscovitine leads to cell cycle arrest at G2 or G1 phase as well
as inhibition of in vivo phosphorylation of vimentin by CDK1.
The 50% inhibitory concentration (IC50) for cell cycle arrest
at prophase is 16 mM. The mechanism of inhibition is mediated
by competitive binding of roscovitine to the ATP binding site
within the catalytic domains of these kinases (9). To investigate
whether roscovitine was able to affect the phosphorylation sig-
FIG. 11. Lack of phosphorylation of GST-gI-wt by CDK6. CDK6 was immu-
noprecipitated with an antibody raised against a peptide of CDK6. The reagents
in the coupled immunoprecipitation kinase assay are listed in tabular format
above each lane (1, present; 2, absent). CDK6 was present in lanes 2 to 5, while
lane 1 is the negative control lacking CDK6. Rb designates the fusion protein of
GST and retinoblastoma protein (GST-Rb); Rb is a positive control substrate for
CDK6. Molecular mass markers are on the left.
FIG. 12. Effects of mutagenesis of threonine 322 on the phosphorylation of
VZV gI. (A) Amino acid sequence of the cytoplasmic tail of gI (7). The under-
lined Ser-343–Pro-344 is the previously described CDK consensus phosphoryla-
tion site; the underlined Thr-322–Pro-323 represents a second potential CDK
phosphorylation site. (B) Phosphorylation results. HeLa cells were transfected
with pTM1 vector only (lane 1), pTM1-gI (lane 2), pTM1-gI-S343A (lane 3),
pTM1-gI-T322A (lane 4), or the dual mutant pTM1-gI-T322A/S343A (lane 5).
The transfected cells were subsequently labeled with [32P]orthophosphate and
harvested as described in the legend to Fig. 5. The gI product was immunopre-
cipitated with MAb 6B5 and analyzed by SDS-PAGE (12 to 18% acrylamide).
The location of gI is indicated in the right margin, along with molecular mass
markers.
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nals of gI in transfected cells, we transfected HeLa cells with
the gI gene and treated some of the transfected cells with vary-
ing concentrations of roscovitine 5 h posttransfection. At the
same time, we labeled another set of transfected cells with
[35S]methionine and [35S]cysteine to monitor gI protein ex-
pression. In the presence of 15 and 30 mM roscovitine, the
phosphorylation signal of gI was reduced by 50 and 70%,
respectively (Fig. 13, lanes 1 to 4). These reductions in gI
phosphorylation were not a consequence of decreased expres-
sion of gI in roscovitine-treated cells, because roscovitine-
treated and untreated cells expressed gI at nearly identical
levels (Fig. 13, lanes 5 to 8). In other words, the vaccinia-pTM1
infection-transfection system was relatively unaffected by ros-
covitine treatment at the indicated concentrations. Because of
the documented specificity of roscovitine, the results obtained
from the inhibition assays described above strongly supported
the conclusion that VZV gI was phosphorylated by a CDK in
human cells. We attempted to confirm the above-mentioned
transfection data by a similar analysis performed in infected
cells. However, the roscovitine treatment markedly inhibited
VZV replication generally, because of the very low inoculum
(about 1 PFU per 1,000 cells).
DISCUSSION
VZV gI contains 354 residues, while gE contains 623 amino
acids. Like its partner, gE, in the VZV gE:gI Fc receptor
complex, gI resembles nonviral cell surface molecules. For
example, VZV gI undergoes endocytosis in clathrin-coated
pits; endocytosis is mediated via a methionine-leucine inter-
nalization motif within the cytoplasmic tail (42). As a second
example, VZV gI is phosphorylated on its cytoplasmic tail, but
the protein kinase catalyzing this event has never been char-
acterized (56). Since VZV gI is often poorly expressed in
infected or transfected cells, it has been less well characterized
(8, 28). Previously, our laboratory mainly used a vaccinia virus-
based transient-transfection system to study VZV glycopro-
teins in HeLa cells (56, 57). The pTM1 plasmid system relies
on a recombinant vaccinia virus expressing bacteriophage T7
RNA polymerase. Since vaccinia virus also encodes protein
kinases, those phosphotransferases may cause complications in
interpreting phosphorylation data obtained from the transient-
transfection system (3, 24). With the aid of an alternative,
nonvaccinia expression system in the present study, we were
able to express VZV gI protein at a similarly high level in
human 293T cells. Our experiments demonstrated that VZV gI
was phosphorylated in the absence of VZV or vaccinia virus
proteins, a result which strongly suggested that a cellular ki-
nase phosphorylated the VZV receptor protein.
Previous mutagenesis studies have eliminated some of the
other serines in the gI endodomain as potential phosphoac-
ceptors (56). This study further documented the location of the
phosphorylation site within VZV gI by investigations with two
different transfection vectors and two different cell substrates:
HeLa cells and 293T cells. In both systems, the serine 343-
proline 344 sequence was essential for gI phosphorylation. The
analysis indicated that a proline residue at position 345 was not
essential for the phosphorylation of VZV gI; however, re-
peated transfection assays showed that the phosphorylation
signal in gI-P345A decreased by 60 to 70% compared with that
of wild-type gI. Thus, proline residue 345 clearly acted as a
secondary structural determinant. When the results of this
phosphorylation study as well as earlier reports were assessed,
the obvious candidate kinase was a proline-directed protein
kinase (35).
To identify the nature of the CDK phosphorylating VZV gI,
we constructed a fusion protein consisting of GST and the
cytoplasmic tail of gI (GST-gI-wt). The in vitro kinase assays
demonstrated that the GST-gI-wt fusion protein was phos-
phorylated by CDK1 (cdc2) and CDK2. Interestingly, GST-
gI-wt was also phosphorylated by a protein kinase called P-
TEFb, a newly discovered CDK (30, 31). The components of
P-TEFb include one subunit which is homologous to cyclins
and is named cyclin T and a second subunit which is now
known to be PITALRE and was renamed CDK9 (13, 45).
Human and Drosophila P-TEFbs exhibit 72% identity and 83%
similarity at an amino acid level.
CDKs are a family of serine-threonine protein kinases, some
FIG. 13. Effects of roscovitine on VZV gI phosphorylation in transfected
cells. HeLa cells were transfected with pTM1 vector (lanes 1 and 5) or pTM1-gI
(lanes 2 to 4 and 6 to 8) and metabolically labeled with either [32P]orthophos-
phate (32P) (lanes 1 to 4) or [35S]methionine and [35S]cysteine (35S) (lanes 5 to
8). During the labeling period, the cells were treated with 0 (lanes 1 to 2 and 5
to 6), 15 (lanes 3 and 7), or 30 (lanes 4 and 8) mM roscovitine. After a 16-h
incubation, the cells were lysed; immunoprecipitated gI was subjected to elec-
trophoresis and analyzed by an Instantimager (Packard Bell). The counts per
minute (CPM) were measured for gI (lanes 2 to 4 and 6 to 8) as well for as an
area corresponding to the location of gI in lanes 1 and 5.
FIG. 14. Network of interactions between the phosphorylation motifs in the
endomains of the VZV gE:gI complex. VZV gE and gI form a receptor complex
through the binding of their ectodomains. Like many other receptors, both
components are phosphorylated on their endodomains. As shown in this report,
a serine 343-proline 344 sequence in the gI endodomain is essential for phos-
phorylation. Prior reports have demonstrated that the cytoplasmic tail of gE is
phosphorylated by CKII at serine and threonine residues between amino acids
593 and 598. Other reports cited in Discussion have documented that both
subunits of CKII are in turn phosphorylated by CDK1. Thus, CDK1 can modify
both components of the VZV Fc receptor complex as part of a network of
phosphorylation events.
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of which are critical in triggering cell cycle progression to
successive phases (G1 to S to G2 to M) (14, 38, 52). Nine
human CDKs have been identified and named: they are CDK1
(cdc2) to CDK9 (14, 45, 52). When other CDK members are
compared with the prototype kinase, CDK1 (cdc2), identical
amino acids range from 36 to 66% (10, 13, 34). CDK1 has a
high sequence homology with CDK2 (65%). The percent
amino acid identities and similarities between CDK1 and
CDK9 are about 47 and 63, respectively (13). Some CDKs also
are restricted in their locations within human tissues; for ex-
ample, CDK1 and CDK2 are not found in neurons whereas
CDK5 is a prominent kinase within neurons (23).
Only a limited number of substrates for CDKs have been
identified. All of the substrates phosphorylated by CDK2,
CDK6, or CDK9 are nuclear proteins, while those phosphor-
ylated by CDK1 include both nuclear and cytoplasmic proteins
(37, 40, 47, 48, 60). Since VZV gI is a cytoplasmic glycoprotein,
the preferential phosphorylation of GST-gI-wt by CDK1 rather
than CDK2 is consistent with the intracellular location of viral
glycoprotein biosynthesis. CDK2 is considered to be active
only inside the nucleus, where it associates with either cyclin E
or cyclin A (4, 47). In contrast, CDK1 is active in both cyto-
plasmic and nuclear compartments. It has long been docu-
mented that the CDK1-cyclin B1 complex is first formed in the
cytoplasm and then translocated into the nucleus before the
nuclear laminae are disassembled, indicating that it is activated
in the cytoplasm (47). In addition, a second kinase-cyclin com-
plex, CDK1-cyclin A, has been purified from a cytoplasmic
compartment, where it is able to phosphorylate the tyrosine
hydroxylase protein (19). When the VZV in vitro and in vivo
experiments are considered together, including the roscovitine
data, the conclusion is that CDK1 is the kinase most likely to
phosphorylate VZV gI. Finally, our results complement to a
remarkable degree the recent paper by Schang et al., which
found that CDK1 or CDK2 but not CDK4 or CDK6 was
required for accumulation of HSV transcripts, viral DNA rep-
lication, and production of infectious HSV (51). The last-men-
tioned paper relied heavily on detailed experimental data ob-
tained with roscovitine and other inhibitors of CDK activity.
The investigators determined that 50 and 100 mM roscovitine
were sufficient to inhibit HSV replication in human embryonic
cells and simian Vero cells, respectively. Specific HSV sub-
strates were not yet identified, although candidate proteins
were discussed.
Based on the results in this report, we postulate an intriguing
network of phosphorylation interactions between the two com-
ponents of the VZV gE:gI complex. The cytoplasmic tail of the
gE constituent of this complex is phosphorylated by CKII at
threonines and serines between amino acid residues 593 and
598; in addition, CKII binds to and coprecipitates with gE (17,
41, 58). CKII is normally active in mammalian cells, and the
phosphorylation sites are not susceptible to dephosphorylation
activity (54). Further, Litchfield et al. and Bosc et al. have
demonstrated that both the alpha and beta subunits of CKII
are phosphorylated by CDK1 (5, 25–27). The phosphorylation
signals of CKII peak at the G2-M phase of a cell cycle. There-
fore, we have constructed a model to depict a plausible inter-
relationship among CDK1, CKII, and the gE endodomain, as
well as the interaction between CDK1 and the gI endodomain
(Fig. 14). The likelihood that this series of phosphorylation and
dephosphorylation reactions in the VZV gE:gI endodomains
will provide signals for internalization and trafficking of the
viral glycoproteins is supported by the recent observation that
a phosphorylation site in the cytomegalovirus gB endodomain
influences its targeting in polarized cells (55).
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